{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:40:57Z","timestamp":1767206457735,"version":"build-2238731810"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Asparaginase-associated pancreatitis (AAP) is one of the most common complications occurring in patients with asparaginase-treated acute lymphoblastic leukemia (ALL). Peg-asparaginase (peg-asp), a chemically recombined asparaginase with lower hyposensitivity and better patient tolerance, is now approved as the first line asparaginase formulation in ALL chemotherapy regimens. Due to the differences in pharmacokinetic characteristics and administration procedure between l-asp and peg-asp, this study aimed to investigate the clinical manifestations of peg-asp-associated pancreatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Patients with peg-asp-associated pancreatitis diagnosed within a 5-year period (July 2014 to July 2019) were identified and retrospectively studied. The clinical manifestations, laboratory findings, and imaging results of patients with AAP were analyzed. AAP patients were further classified into mild\/moderate and severe groups based on criteria used in previous studies. Clinical outcomes were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 38 patients were enrolled in this study. The underlying disease included ALL (n=35) and lymphoma (n=3). The majority of patients developed AAP during the first phase, called remission induction (n=26, 68.4%), after a median of 2 peg-asp doses (range: 1\u201311). The DVLP regimen (n=23) is the most common peg-asp regimen used in AAP patients. Abdominal pain occurred after a median of 14.5 days (range: 1\u201350) from the last peg-asp administration, accompanied by abdominal distension (n=14), nausea (n=17), vomiting (n=21), and fever (n=19). Serum amylase elevation was reported in all AAP patients, of whom 65.8% (n=25) exhibited an elevation in the level of this enzyme three times the upper normal level, fulfilling the Atlanta criteria. The level of serum lipase (median days of elevation=23 days, range: 4\u201375) was significantly elevated compared with that of serum amylase (median days of elevation=9 days, range: 2\u201371) and persisted at a markedly high level after the level of serum amylase returned to normal. Common local complications included abdominal ascites (n=10) and peripancreatic fluid collection (n=8). Approximately 42.1% (n=16) of patients with severe AAP experienced systemic complications (septic shock or hypovolemic shock) or severe local complications (pseudocyst), among whom 5 failed to recover. Approximately 84.8% (n=28\/33) of the remaining patients resumed chemotherapy; among them, peg-asp formulation in 30.3% (n=10\/33) of these patients was adjusted, while asparaginase treatment in 39.4% (n=13\/33) was permanently discontinued. Five patients experienced an AAP relapse in later stages of asparaginase treatment. Comparison between mild\/moderate and severe AAP patients showed a statistically significant difference in the number of pediatric intensive care unit stays (p=0.047), survival rate (p=0.009), AAP prognosis (p=0.047), and impacts on chemotherapy (p=0.024), revealing a better clinical outcome in mild\/moderate AAP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early recognition and management of AAP is essential in reversing the severity of AAP. The existing AAP criteria had a low strength in determining the severity of pediatric AAP. A well-defined AAP definition could help distinguish patients with high anticipated risk for redeveloping AAP and ALL relapse, in order to prevent unnecessary withdrawal of asparaginase. Our study could serve as a basis for conducting future large cohort studies and for establishing an accurate definition of pediatric AAP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2020.538779","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T02:43:20Z","timestamp":1603853000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["RETRACTED: Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study"],"prefix":"10.3389","volume":"10","author":[{"given":"Yun-yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-shi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-tao","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.07.009","article-title":"Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia","volume":"61","author":"Narta","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-199707010-00005","article-title":"Acute lymphoblastic leukaemia: a guide to asparaginase and pegaspargase therapy","volume":"7","author":"Ettinger","year":"1997","journal-title":"BioDrugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-74643-7_83","article-title":"More is better! Update of Dana-Farber Cancer Institute\/Children\u2019s Hospital childhood acute lymphoblastic leukemia trials","volume":"33","author":"Sallan","year":"1990","journal-title":"Haematol Blood Transfus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149129","article-title":"L-asparaginase and PEG asparaginase\u2013past, present, and future","author":"Keating","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1078155219838316","article-title":"Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management","volume":"26","author":"Bade","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2018_180214N121","article-title":"Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL)","volume":"65","author":"Helbig","year":"2018","journal-title":"Neoplasma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2402-3","article-title":"Asparaginase in the treatment of non-ALL hematologic malignancies","volume":"73","author":"Emadi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000589","article-title":"A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children\u2019s Oncology Group Study AALL08P1","volume":"38","author":"Rodriguez","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302779","article-title":"Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus","volume":"62","author":"Banks","year":"2013","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12407","article-title":"Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"162","author":"Samarasinghe","year":"2013","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200003)34","article-title":"Pegaspargase-induced pancreatitis","volume":"34","author":"Alvarez","year":"2000","journal-title":"Med Pediatr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12733","article-title":"Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol","volume":"165","author":"Raja","year":"2014","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21037","article-title":"Predicting asparaginase-associated pancreatitis","volume":"49","author":"Knoderer","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4811-9_69","article-title":"The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia","volume":"457","author":"Asselin","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2165\/11632990-000000000-00000","article-title":"L-asparaginase-induced pancreatic injury is associated with an imbalance in plasma amino acid levels","volume":"12","author":"Minowa","year":"2012","journal-title":"Drugs R D"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.203","article-title":"Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol","volume":"31","author":"Wolthers","year":"2017","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5812","article-title":"Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjh.12016","article-title":"Asparaginase-associated pancreatitis in children","volume":"159","author":"Raja","year":"2012","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000827","article-title":"Risk Factors for Asparaginase-associated Pancreatitis: A Systematic Review","volume":"51","author":"Oparaji","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2015.1055868","article-title":"Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia","volume":"32","author":"Raja","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"}],"updated-by":[{"DOI":"10.3389\/fonc.2021.709636","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"record-id":"29744"},{"DOI":"10.3389\/fonc.2021.709636","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.538779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T09:19:20Z","timestamp":1711617560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.538779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":25,"alternative-id":["10.3389\/fonc.2020.538779"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.538779","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"article-number":"538779"}}